Literature DB >> 10726829

Chemotherapy with Adriamycin (doxorubicin) and CCNU (lomustine) in four children with recurrent craniopharyngioma.

R J Lippens1, J J Rotteveel, B J Otten, H Merx.   

Abstract

BACKGROUND: The prognosis of craniopharyngioma in children after subtotal surgical removal, followed by irradiation of remaining tumour with 50 Gy, is better than usually reported. In our subjects we found a relapse rate of 5% in the last 20 years. The treatment of recurrences forms a special problem because the possibilities of adjuvant radiotherapy are restricted. We report on a chemotherapeutic treatment after multiple or very rapid recurrences of craniopharyngioma in four children.
METHODS: Four children experienced their first tumour recurrence at respectively 3, 8, 50 and 59 months after the initial treatment. New neurosurgical attempts to remove the recurring tumour, and in one patient a second course of radiotherapy, were performed, but there were two or more recurrences in these children, resulting in further restriction of surgical or radiotherapeutical possibilities. Chemotherapy was given, consisting of five intravenous ambulatory courses of Adriamycin (doxorubicin) (33 mg/m2/day, continuously over 3 days) together with oral CCNU (lomustine) (80 mg/m2 at day 1) at 6-weeks intervals.
RESULTS: After the chemotherapy there was no further tumour recurrence after 12, 10, 3 and 3 years respectively. In the third patient a cystic relapse occurred after 3 years' remission. In the fourth patient a complete regression was observed of the cystic part of the tumour. The side-effects of the chemotherapy consisted of alopecia and bone marrow depression. No signs of cardiomyopathy have been found.
CONCLUSION: Treatment of recurrent craniopharyngioma in children by chemotherapy with anthracyclines and nitrourea-derivates may be effective.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10726829     DOI: 10.1016/s1090-3798(98)80040-8

Source DB:  PubMed          Journal:  Eur J Paediatr Neurol        ISSN: 1090-3798            Impact factor:   3.140


  6 in total

Review 1.  Management of craniopharyngiomas.

Authors:  N Karavitaki
Journal:  J Endocrinol Invest       Date:  2014-03       Impact factor: 4.256

2.  MGMT immunoexpression in adamantinomatous craniopharyngiomas.

Authors:  Sayid Shafi Zuhur; Ahmet Murat Müslüman; Canan Tanık; Ozcan Karaman; Feyza Yener Oztürk; Ayşenur Ozderya; Hanife Ozkayalar; Yunus Aydın; Yüksel Altuntaş
Journal:  Pituitary       Date:  2011-12       Impact factor: 4.107

3.  Craniopharyngioma.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2001-01       Impact factor: 3.598

Review 4.  A systematic review of the results of surgery and radiotherapy on tumor control for pediatric craniopharyngioma.

Authors:  Aaron J Clark; Tene A Cage; Derick Aranda; Andrew T Parsa; Peter P Sun; Kurtis I Auguste; Nalin Gupta
Journal:  Childs Nerv Syst       Date:  2012-10-23       Impact factor: 1.475

5.  Endocrinologic, neurologic, and visual morbidity after treatment for craniopharyngioma.

Authors:  Michael E Sughrue; Isaac Yang; Ari J Kane; Shanna Fang; Aaron J Clark; Derrick Aranda; Igor J Barani; Andrew T Parsa
Journal:  J Neurooncol       Date:  2010-06-10       Impact factor: 4.130

6.  Magnetic Temperature-Sensitive Solid-Lipid Particles for Targeting and Killing Tumor Cells.

Authors:  Małgorzata Świętek; Rostyslav Panchuk; Nadia Skorokhyd; Peter Černoch; Nataliya Finiuk; Olha Klyuchivska; Martin Hrubý; Matúš Molčan; Walter Berger; Jirí Trousil; Rostyslav Stoika; Daniel Horák
Journal:  Front Chem       Date:  2020-04-09       Impact factor: 5.221

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.